Alembic Pharmaceuticals Ltd Q1 FY2025 Concall Summary

Key Takeaways

• India branded business resilient despite heatwave: Grew 9% to ₹572 crores, with specialty therapies leading and acute therapies outperforming a disrupted market.
• U.S. business delivers 18% growth but carries a lumpiness warning: Management guided to 10–12% full-year growth against persistent double-digit price erosion, and flagged that Q1 included non-recurring lumpy revenue.
• Non-OSD ramp-up is the margin story, but it is early: New facilities for injectables, ophthalmics and oncology are built and beginning to contribute, yet utilization remains low and the 18–20% EBITDA margin target sits 2–3 years out.
• API business declined and recovery is back-half loaded: A customer’s FDA issue, pricing pressure and lumpy order timing compressed the quarter; management expects a return to 10% YoY growth only by year-end.
• What to watch next quarter: Whether the ~10 planned Q2 launches materialize and begin converting the non-OSD capacity into revenue, and whether Entresto’s path clears after other parties’ litigation outcomes.

India Branded Formulations

• Specialty-led growth with acute resilience: The 9% growth to ₹572 crores was driven by gastroenterology, gynaecology, antidiabetic and ophthalmology, while acute therapies held up better than the broader market despite disruption.
• Heatwave created localised demand distortion: Excessive heat in specific geographies produced unnatural market disturbances that weighed on performance during the quarter.
• New launches contributing meaningfully: Several promising new launches in Q1 added to momentum, and the category overall continues to perform well.
• Two new therapy divisions added: A new gynaecology division and a new cardiac division have been added to the sales force, expanding reach without plans for further major sales force expansion this year.
• Consistent IPM outperformance is the baseline target: Under normal market conditions, management expects to outperform the IPM by at least a couple of basis points, excluding the Animal Health business.

Shaunak Amin: "I don't want to get into the multiple reasons of why the market grows slowly. But against a normalization of the market... if RPM is growing in line, we expect to outperform the IPM by at least a couple of basis points consistently."

U.S. Generics

• Strong quarter with a lumpiness caveat: Revenue grew 18%, but management explicitly stated that some of this was lumpy and would not recur, while maintaining a full-year growth target of 10–12%.
• Double-digit price erosion persists: Management sees no relief on pricing, characterising the environment as still firmly in double-digit erosion territory, not single-digit.
• ~10 launches planned for Q2: Roughly half are oral solids and the rest span newer dosage forms including general injectables and prefill syringes, where a few launches may arrive by quarter-end.
• Non-OSD capacity is built but underutilised: Plants for oncology, ophthalmics and injectables are operational, with ophthalmics running well and oncology picking up traction, though overall utilisation remains low and tough to quantify.
• OSD will remain dominant even as mix shifts: Management expects oral solids to stay above 50% of the portfolio in the long run, down from nearly 100% four to five years ago, with growth increasingly coming from other dosage forms.
• Lenalidomide is a non-event for Alembic: The company settled late and is a good couple of years from launch, well behind earlier waves of entrants; management expects little market left by the time it arrives.
• Entresto launch timing hinges on others’ litigation: Alembic has already settled with Novartis but cannot launch immediately under those terms; if another party launches, an opportunity may open, with better visibility expected in a couple of weeks.

Pranav Amin: "I'd like to grow it by about 10% to 12% this year. And we'll hold that true. It's a combination of the competition and the price erosion that we see."

Pranav Amin: "That's why when you all ask for the price erosion, and when I do see price erosion, I'm seeing double digit. I'm not seeing single-digit price erosion."

Pranav Amin: "No. we were very late on this product. So here's a whole bunch of people before us. So our settlement is much later, and I don't expect there'll be much of market left by the time we get in."

API Business

• Multiple headwinds compressed the quarter: Lower sales stemmed from three factors: lumpy order timing that will reverse by year-end, reduced offtake from one customer facing its own FDA issue, and pricing pressure that caused loss of some business.
• Customer FDA issue transferred market share elsewhere: The problem is at the customer level and remains unresolved; the lost volume has shifted to competitors, and management aims to compensate with other business.
• Recovery expected only by year-end: API business is projected to return to growth and deliver roughly 10% year-on-year growth by the close of the fiscal year.
• Gross margin stable despite lower API share: Management reiterated comfort with 70%-plus gross margins, attributing quarterly variations to product mix and consumption patterns rather than structural erosion.

Margins & Balance Sheet

• EBITDA margin improvement expected YoY: Last quarter benefited from one-time items; on a year-on-year basis, margins are expected to improve as the year progresses.
• The 18–20% margin target is a 2–3 year journey: The pathway runs through better utilisation of new facilities, with R&D already optimised; quarterly progress will be gradual rather than step-change.
• Working capital expanded on launch inventory: Gross borrowings rose as new launches required inventory buildup and multiple plants became operational simultaneously; inventory days are expected to normalise by March 2025.
• Standalone vs consolidated profit divergence explained: A sharp jump in standalone profits did not flow through to consolidated numbers because of inventory buildup in the U.S. for new launches, creating unrealised profit in standalone books.
• U.S. generics remain profitable ex-R&D: Even after including costs of new facilities shared across all markets, the U.S. generics business stays in positive territory when R&D is excluded.
• Full-year tax rate guided at ~17% standalone: The rate depends on subsidiary profits and may vary accordingly.

Pranav Amin: "I said we do expect that the margins over a 2-3 year period go up closer to the 18% to 20% kind of ranges. And that will happen as the new facilities get better utilized, and we've already optimized the R&D."

Animal Health & ROW

• Animal Health grew 23% on brand strength: A basket of strong brands drove outperformance, supported by a new livestock division added in the prior financial year.
• Momentum expected to sustain near historical CAGR: Management’s conservative expectation is for growth in and around the compound annual growth rate of the last three years.
• ROW muted by supply constraints, not demand: Growth was subdued because of constrained supplies; resolution is expected in one to two quarters, with better growth in the second half of the year.

Regulatory & Facilities

• F1 OSD facility cleared with zero observations: The U.S. FDA inspected the oral solid dosage facility recently and issued no observations, a clean outcome that de-risks the core manufacturing base.
• F4 formulation facility ramping up: Built a couple of years ago, the plant is increasingly receiving product transfers and scaling operations.
• F1 debottlenecking under evaluation: Management is examining constraints in specific areas of the F1 facility with a view to expanding capacity.
• Selexipag launch still distant: The product is not expected to launch until FY26 or FY27; timelines remain early-stage and management did not have precise dates at hand.

Guidance & Commitments

Key Metrics